176 related articles for article (PubMed ID: 30789400)
1. Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
Novruzov F; Mehmetbeyli L; Aliyev JA; Abbasov B; Mehdi E
Clin Nucl Med; 2019 Jun; 44(6):e415-e417. PubMed ID: 30789400
[TBL] [Abstract][Full Text] [Related]
2. Malignant insulinoma: 18F-DOPA and 68Ga-DOTATATE PET/CT and treatment with 177Lu-DOTATATE.
Erhamamcı S; Sager S; Asa S; Uslu L; Akgun E; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):383-386. PubMed ID: 32487444
[No Abstract] [Full Text] [Related]
3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
5. The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma.
Novruzov F; Aliyev JA; Jaunmuktane Z; Bomanji JB; Kayani I
Clin Nucl Med; 2015 Jan; 40(1):47-9. PubMed ID: 25275413
[TBL] [Abstract][Full Text] [Related]
6. Complete Resolution of Disease After Peptide Receptor Radionuclide Therapy in a Patient of Metastatic Insulinoma.
Verma P; Malhotra G; Dodamani MH; Lila AR; Asopa RV; Bandgar TR
Clin Nucl Med; 2022 Jan; 47(1):e77-e78. PubMed ID: 34284474
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
Davì MV; Bodei L; Ferdeghini M; Falconi M; Testoni M; Paganelli G; Oliani C; Lo Cascio V; Francia G
Endocr Pract; 2008 Mar; 14(2):213-8. PubMed ID: 18308661
[TBL] [Abstract][Full Text] [Related]
8. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Acar E; Çapa Kaya G; Durak H
Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):53-4. PubMed ID: 26562579
[TBL] [Abstract][Full Text] [Related]
10. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
11. Gallbladder Visualization in Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE: A Potential Mimicker of Hepatic Metastases.
Diekmann J; Werner RA; Ross TL; Derlin T
Clin Nucl Med; 2020 Dec; 45(12):e521-e522. PubMed ID: 32657878
[TBL] [Abstract][Full Text] [Related]
12. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564
[TBL] [Abstract][Full Text] [Related]
13.
Shah R; Sehemby M; Garg R; Purandare N; Hira P; Mahajan A; Lele V; Malhotra G; Verma P; Rojekar A; Dalvi A; Uchino S; Rastogi S; Lila A; Patil V; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2022 Feb; 96(2):190-199. PubMed ID: 34498757
[TBL] [Abstract][Full Text] [Related]
14. Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma.
Fischbach J; Gut P; Matysiak-Grześ M; Klimowicz A; Gryczyńska M; Waśko R; Ruchała M
Neuro Endocrinol Lett; 2012; 33(3):273-8. PubMed ID: 22635083
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTATATE PET/CT imaging for insulinoma in MEN1 patient with endogenous hyperinsulinemic hypoglycemia: A case report.
Liu Y; Zhao X; Zhang J; Wang J; Zhang Z; Dai M; Wang N; Jing F; Wang T; Tian W
Medicine (Baltimore); 2022 Aug; 101(34):e30252. PubMed ID: 36042606
[TBL] [Abstract][Full Text] [Related]
16. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.
Romeo S; Milione M; Gatti A; Fallarino M; Corleto V; Morano S; Baroni MG
Horm Res; 2006; 65(3):120-5. PubMed ID: 16479142
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T
Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
[TBL] [Abstract][Full Text] [Related]
20.
Tuzcu SA; Pekkolay Z; Kılınç F; Tuzcu AK
J Nucl Med Technol; 2017 Sep; 45(3):198-200. PubMed ID: 28798227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
